Full-Time

Senior Manager/Associate Director

Marketing Operations & Commercial Review

Xenon Pharmaceuticals

Xenon Pharmaceuticals

201-500 employees

Clinical-stage neurological disorder therapeutics developer

Compensation Overview

$160.2k - $240.7k/yr

+ Target Bonus + Stock Options

Boston, MA, USA

Hybrid

Hybrid role; minimum two onsite days per week at Needham/Boston offices.

Category
Growth & Marketing (1)
Required Skills
Veeva

Get referred to Xenon Pharmaceuticals

See people who can refer or advise you

Requirements
  • Bachelor’s degree required
  • 6–10+ years of experience in marketing operations within pharmaceutical/biotech or agency environments
  • Demonstrated experience with MLR/CRC processes and governance
  • Demonstrated experience with Campaign operations and asset lifecycle management
  • Demonstrated experience with Vendor and agency management
  • Strong understanding of regulatory and compliance requirements in pharmaceutical marketing
Responsibilities
  • Lead the design, optimization, and execution of the Commercial Review Committee (CRC/MLR) process, ensuring alignment with Marketing, Regulatory, Legal, Medical, and Compliance stakeholders
  • Continuously assess and improve CRC workflows, identifying bottlenecks, redundancies, and cycle-time challenges; proactively propose and implement solutions to enhance efficiency and quality
  • Serve as primary CRC operations lead, either directly coordinating reviews or managing an outsourced/vendor-supported model depending on capacity and business needs
  • Establish and manage CRC governance forums, including coordinating CRC steering committees, setting agendas, and aligning stakeholders on process improvements and priorities
  • Lead and coordinate the Executive Review Committee escalation governance committee
  • Partner with IT and cross-functional teams to manage systems supporting CRC workflows (e.g., Veeva PromoMats or similar), including user access, license management, and system enhancements
  • Lead the development and delivery of training programs for CRC processes, systems, and ways of working across Marketing and cross-functional partners
  • Stay current on industry best practices, emerging technologies, and innovation (including AI-enabled content and review solutions); identify opportunities and drive adoption of new capabilities to improve efficiency and scalability
  • Collaborate cross-functionally to evaluate and enhance the end-to-end content lifecycle, including: Content intake and planning; Content creation and modular content strategy; Digital asset management (DAM) and content libraries; Content reuse and optimization
  • Develop and align stakeholders to a forward-looking roadmap for content operations maturity and implement prioritized enhancements
  • Lead the vendor selection, process development, and day to day coordination with marketing and other partners on materials printing and fulfillment management
  • Partner closely with Marketing leadership to forecast review volume, assess capacity, and plan for fluctuations in workload and complexity
  • Proactively identify risks related to throughput, timelines, or resource constraints and develop mitigation plans in alignment with cross-functional stakeholders
  • Drive integrated planning and scheduling of marketing materials through the CRC process to ensure timely delivery of key campaigns, launches, and field materials
  • Act as a central point of coordination across Marketing, Regulatory, Legal, Medical, and Compliance to ensure alignment on priorities and timelines
  • Manage external vendors and agency partners supporting CRC operations (if outsourced components are implemented)
  • Print, fulfillment, and material distribution
  • Define scope of work, performance expectations, and service-level agreements (SLAs) for vendors
  • Monitor vendor performance against KPIs and drive continuous improvement
  • Track budgets related to marketing operations and vendor services, ensuring efficient and compliant resource utilization
  • Define, implement, and track KPIs for marketing operations and CRC performance, including cycle times, approval rates, rework levels, and throughput
  • Develop and maintain operational dashboards and reporting to provide transparency into process performance and identify improvement opportunities
  • Use data-driven insights to continuously refine processes and improve effectiveness
  • Develop and propose short- and long-term objectives for the function in accordance with overall Company strategies and plans
  • Recruit, lead, direct, develop, coach and evaluate direct reports, if any, in accordance with the Company’s Human Resource policies and practices
  • Act in accordance with Company policies, including, for example, the Code of Business Conduct and Ethics and ensure policies are understood and followed by direct reports, if any
  • Some international travel may be required
  • Other duties as assigned
Desired Qualifications
  • Experience in launch or pre-launch environments, particularly in specialty or rare disease
  • Experience with Veeva PromoMats or similar systems
  • Exposure to omnichannel marketing and modular content strategies
  • Experience implementing process improvements or transformation initiatives
Xenon Pharmaceuticals

Xenon Pharmaceuticals

View

Xenon develops therapies for neurological disorders, especially epilepsy, in a clinical-stage biopharma setting, using research, partnerships, and licensing to move candidates toward commercialization. Its products are designed to act on neurological and genetic targets, with XEN007 in Phase 2 for treatment-resistant pediatric absence epilepsy illustrating its development pathway and reliance on clinical testing. The company differentiates itself by focusing on genetics-informed neurology and a pediatric, targeted epilepsy pipeline supported by collaborations rather than broad, one-size-fits-all approaches. The goal is to discover, develop, and eventually bring to patients therapies that address unmet neurological needs, advancing outcomes through a strong clinical pipeline and strategic partnerships.

Company Size

201-500

Company Stage

IPO

Headquarters

Burnaby, Canada

Founded

1996

Get referred to Xenon Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Positive Phase 3 focal onset seizure data supports an NDA filing in Q3 2026.
  • $837.6 million financing lifted cash to about $1.34 billion, funding operations into 2029.
  • Successful expansion into depression or bipolar depression could turn Xenon into a multi-indication neurology company.

What critics are saying

  • Xenon remains pre-revenue, so launch delays would keep losses and cash burn high.
  • FDA rejection or label restrictions on azetukalner would crush the lead-asset valuation.
  • Failure in MDD or bipolar depression trials would leave Xenon overly dependent on epilepsy.

What makes Xenon Pharmaceuticals unique

  • Azetukalner is a novel Kv7 potassium-channel opener for epilepsy and mood disorders.
  • Xenon has multiple Phase 3 readouts across epilepsy, MDD, and bipolar depression.
  • The pipeline includes early sodium-channel and pain programs beyond azetukalner.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Short-& Long-term Disability

Accidental Death & Dismemberment

Life Insurance

Employee Assistance Program

401(k) Company Match

Stock Options

Tuition Reimbursement

Paid Vacation

Paid Sick Leave

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
Xenon Pharmaceuticals Inc.
Jan 5th, 2026
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference

Xenon to present at the 44th Annual J.P. Morgan Healthcare Conference. VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) - Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026. | Date: | Monday, January 12, 2026 | | Time: | 9:00-9:40am Pacific Time (12:00-12:40pm Eastern Time) | | Webcast: | Webcast - 44th Annual J.P. Morgan Healthcare Conference | | Presenter: | Ian Mortimer, President and Chief Executive Officer, Xenon Pharmaceuticals | | / | / | A live audio webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay following the event. The above-mentioned dates and times are subject to change. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. Xenon's lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Na[V] 1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow Xenon Pharmaceuticals Inc. on LinkedIn and X. Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner. Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and potential results from clinical studies; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of its and its partners' product candidates; the efficacy of its clinical study designs; its ability to successfully develop and achieve milestones in its azetukalner and other pipeline and development programs, including the anticipated filing of INDs and NDAs; the timing and results of its interactions with regulators; its ability to successfully develop and obtain regulatory approval of azetukalner and its other product candidates; and anticipated timing of topline data readout from its clinical studies of azetukalner. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond its control, include, but are not limited to: clinical studies may not demonstrate safety and efficacy of any of its or its collaborators' product candidates; promising results from pre-clinical development activities or early clinical study results may not be replicated in later clinical studies; its assumptions regarding its planned expenditures and sufficiency of its cash to fund operations may be incorrect; its ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of its or its collaborators' product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Xenon Pharmaceuticals Inc. may not achieve additional milestones in its proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation or completion of clinical studies; the impact of market, industry, and regulatory conditions on clinical study enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in its filings with the U.S. Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and Xenon Pharmaceuticals Inc. assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Xenon Pharmaceuticals Inc.
Jun 24th, 2025
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

Xenon announces appointment of Darren Cline as Chief Commercial Officer.